Compare OCC & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCC | PSTV |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.8M | 46.4M |
| IPO Year | 2001 | 2016 |
| Metric | OCC | PSTV |
|---|---|---|
| Price | $7.24 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 121.8K | ★ 3.9M |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 290.91 | 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $87,828,590.00 | $5,213,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.03 | N/A |
| 52 Week Low | $2.40 | $0.16 |
| 52 Week High | $11.50 | $2.08 |
| Indicator | OCC | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 37.09 |
| Support Level | $4.35 | $0.21 |
| Resistance Level | $9.89 | $0.32 |
| Average True Range (ATR) | 0.84 | 0.03 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 48.20 | 6.51 |
Optical Cable Corp manufactures tight-buffered fiber optic & copper data communication cables, data communication connectivity solutions for enterprise markets, and customized solutions for specialty use & harsh environments. Its products and services include designs and customized products for specialty applications and harsh environments, cabling, connectors, patch cords, assemblies, racks, cabinets, datacom enclosures, patch panels, faceplates, and multi-media boxes. The company supplies its products and services to industries such as the military, industrial, mining, petrochemical, renewable energy and broadcast applications, and for the wireless carrier market.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).